-
1Academic Journal
Συγγραφείς: G. M. Zainetdinova, R. F. Khakimova, G. R. Ryzhova, Г. М. Зайнетдинова, Р. Ф. Хакимова, Г. Р. Рыжова
Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 5 (2025); 97-103 ; Российский вестник перинатологии и педиатрии; Том 70, № 5 (2025); 97-103 ; 2500-2228 ; 1027-4065
Θεματικοί όροι: синдром Черджа-Стросс, bronchial asthma, eosinophilic granulomatosis with polyangiitis, Charge-Strauss syndrome, бронхиальная астма, эозинофильный гранулематоз с полиангиитом
Περιγραφή αρχείου: application/pdf
Relation: https://www.ped-perinatology.ru/jour/article/view/2264/1634; Emmi G., Bettiol A., Gelain E., Bajema I.M., Berti A., Burns S., et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023; 19(6): 378–393. DOI: s41584-023-00958-w; Jakes R.W., Kwon N., Nordstrom B., Goulding R., Fahrbach K., Tarpey J., et al. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin Rheumatol. 2021; 40(12): 4829–4836. DOI:10.1007/s10067-021-05783-8; Watts R.A., Hatemi G., Burns J.C., Mohammad A.J. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022; 18(1): 22–34. DOI:s41584-021-00718-8; Lee J.H., Hong S.H., Yu I., Chang M.S., Park S., Lee S.J., et al. Incidence, Prevalence, and Mortality of Eosinophilic Granulomatosis With Polyangiitis in Korea: A Nationwide Population-Based Study. Allergy Asthma Immunol Res. 2024; 16(2): 168. DOI:10.4168/aair.2024.16.2.168; Fina A., Dubus J., Tran A., Derelle J., Reix P., Fayon M., et al. Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRare® cohort. Pediatric Pulmonology. 2018; 53(12): 1640–1650. DOI:10.1002/ppul.24089; Liu X., Wang L., Zhou K., Hua Y., Shi X., Wang C. A delayed diagnosis of eosinophilic granulomatosis with polyangiitis complicated with extensive artery occlusion of lower extremities in children: case report and literature review. Pediatr Rheumatol. 2019; 17(1): 26. DOI:10.1186/s12969-019-0331-8; Theofilis P., Vordoni A., Koukoulaki M., Vlachopanos G., Kalaitzidis R.G. Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatol Int. 2022; 42(5): 759–770; Hu J.K., Yaghi M., Milikowski C., Elman S.A. Eosinophilic granulomatosis and polyangiitis unmasked by dupilumab. Int J Dermatology. 2023; 62(6): 839–840. DOI:10.1111/ijd.16670; Alexander G., Moore S.A., Lenert P.S. Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review. Clin Rheumatol. 2024; 43(6): 2153–2165. DOI:10.1007/s10067-024-07000-8; Wieczorek S., Hellmich B., Gross W.L., Epplen J.T. Associations of Churg-Strauss syndrome with the HLA–DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody–associated vasculitides: Comment on the article by Vaglio et al. Arthritis & Rheumatism. 2008; 58(1): 329–330. DOI:10.1002/art.23209; Tsurikisawa N., Oshikata C., Watanabe M., Tsuburai T., Kaneko T., Saito H. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. Clin Experimental Allergy. 2018; 48(10): 1305–1316. DOI:10.1111/cea.13209; Zwerina J., Bach C., Martorana D., Jatzwauk M., Hegasy G., Moosig F., et al. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology. 2011; 50(10): 1823–1827. DOI:10.1093/rheumatology/keq445; Vega Villanueva K.L., Espinoza L.R. Eosinophilic Vasculitis. Curr Rheumatol Rep. 2020; 22(1): 5. DOI:10.1007/s11926-020-0881-2; Mukherjee M., Thomas S.R., Radford K., Dvorkin-Gheva A., Davydchenko S., Kjarsgaard M., et al. Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody–Negative Eosinophilic Granulomatosis with Polyangiitis. Am J Respir Crit Care Med. 2019; 199(2): 158–170. DOI:10.1164/rccm.201804-0809OC; Fukuchi M., Kamide Y., Ueki S., Miyabe Y., Konno Y., Oka N., et al. Eosinophil ETosis–Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 2021; 73(9): 1683–1693. DOI:10.1002/art.41727; Khoury P., Grayson P.C., Klion A.D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014; 10(8): 474–483; Fagni F., Bello F., Emmi G. Eosinophilic Granulomatosis With Polyangiitis: Dissecting the Pathophysiology. Front Med. 2021; 8: 627776; Fijolek J., Radzikowska E. Eosinophilic granulomatosis with polyangiitis — Advances in pathogenesis, diagnosis, and treatment. Front Med. 2023 3; 10: 1145257; Cottin V., Bel E., Bottero P., Dalhoff K., Humbert M., Lazor R., et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews. 2017; 16(1): 1–9; Berti A., Volcheck G.W., Cornec D., Smyth R.J., Specks U., Keogh K.A. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respiratory Medicine. 2018; 142: 66–72; Wludarczyk A., Szczeklik W. Neurological manifestations in ANCA-associated vasculitis — assessment and treatment. Expert Review of Neurotherapeutics. 2016; 16(8): 861–3. DOI:10.1586/14737175.2016.1165095; Micheletti R.G., Chiesa Fuxench Z., Craven A., Watts R.A., Luqmani R.A., Merkel P.A., et al. Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis & Rheumatology. 2020; 72(10): 1741–1747. DOI:10.1002/art.41310; Durel C.A., Sinico R.A., Teixeira V., Jayne D., Belenfant X., Marchand-Adam S., et al. Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology (Oxford). 2021; 60(1): 359–365; Кузнецова А.С., Мельник С.И., Гаврилов П.В., Сергеев К.В., Трусова О.В. Особенности диагностического поиска при синдроме Черджа–Стросс. Клинический случай. Педиатрия. Consilium Medicum. 2023; 2: 198–204.; Nie N., Liu L., Bai C., Wang D., Gao S., Liu J., et al. Eosinophilic granulomatous polyangiitis with central nervous system involvement in children: a case report and literature review. Front Immunol. 2024; 15: 1406424; Бронхиальная астма. Клинические рекомендации, 2024. https://cr.minzdrav.gov.ru/view-cr/359_3 Ссылка активна на 25.07.2025; Jariwala M., Laxer R.M. Childhood GPA, EGPA, and MPA. Clin Immunol. 2020; 211: 108325. DOI:10.1016/j.clim.2019.108325; Barbosa Rodrigues A., Oliveira-Ramos F., Ferreira R., Camilo C., Oliveira T., Costa-Reis P. Eosinophilic Granulomatosis with Polyangiitis — description of a pediatric patient with severe disease. ARP Rheumatol. 2023; 2(2): 160–165; Лев Н.С. Эозинофильный гранулематоз с полиангиитом (синдром Черджа-Стросс). В кн.: Клинические варианты интерстициальных болезней легких в детском возрасте. Лев Н.С., Мизерницкий Ю.Л. М: ИД «Медпрактика-М», 2021: 153–160.; Cottin V., Bel E., Bottero P., Dalhoff K., Humbert M., Lazor R., et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Eur Respir J. 2016; 48(5): 1429–1441. DOI:10.1183/13993003.00097-2016
-
2Academic Journal
Συγγραφείς: Okhotnikova, O. M., Kvacheniuk, O. H., Mellina, K. V., Ponochevna, O. V.
Πηγή: Modern Pediatrics. Ukraine; № 1(105) (2020): Modern pediatrics. Ukraine; 49-62
Современная педиатрия. Украина; № 1(105) (2020): Современная педиатрия. Украина; 49-62
Сучасна педіатрія. Україна; № 1(105) (2020): Сучасна педіатрія. Україна; 49-62Θεματικοί όροι: еозинофільний гранульоматоз з поліангіїтом, синдром Чарджа—Стросса, гіпереозинофільний синдром, бронхіальна астма, эозинофильный гранулематоз с полиангиитом, гиперэозинофильный синдром, бронхиальная астма, 03 medical and health sciences, 0302 clinical medicine, eosinophilic granulomatosis with polyangiitis, Churg-Strauss syndrome, hypereosinophilic syndromes, asthma, 3. Good health
Περιγραφή αρχείου: application/pdf
-
3Academic Journal
Συγγραφείς: A.S. Asekritova, E.A. Emelyanova, A.P. Dalbaraeva
Πηγή: Yakut Medical Journal. :122-125
Θεματικοί όροι: ANCA-ассоциированные васкулиты, эозинофильный гранулематоз с полиангиитом, синдром Чарджа-Стросс, бронхиальная астма, EGPA, 3. Good health
-
4Academic Journal
Συγγραφείς: T. V. Beketova, Т. В. Бекетова
Πηγή: Rheumatology Science and Practice; Vol 61, No 5 (2023); 531-536 ; Научно-практическая ревматология; Vol 61, No 5 (2023); 531-536 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: классификационные критерии, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, classification criteria, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3347/2312; Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1): 1-11. doi:10.1002/art.37715; Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107. doi:10.1002/art.1780330807; Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg – Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100. doi:10.1002/art.1780330806; Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-227. doi:10.1136/ard.2006.054593; Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford). 2010;49(11):2181-2190. doi:10.1093/rheumatology/keq244; Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187-192. doi:10.1002/art.1780370206; Schönermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology (Oxford). 2001;40(2):178-184. doi:10.1093/rheumatology/40.2.178; Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, et al.; RAVE-ITN Research Group. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166-1169. doi:10.1136/annrheumdis-2015-208073; Syed R, Rehman A, Valecha G, El-Sayegh S. Pauci-immune crescentic glomerulonephritis: An ANCA-associated vasculitis. Biomed Res Int. 2015;2015:402826. doi:10.1155/2015/402826; Бекетова ТВ, Фролова НФ, Столяревич ЕС, Волков МЮ, Котенко ОН, Александрова ЕН. Проблемы диагностики и лечения АНЦА-ассоциированных системных васкулитов: в фокусе АНЦА-негативный pauci-иммунный гломерулонефрит. Научно-практическая ревматология. 2016;54(5):543-552. doi:10.14412/1995-4484-2016-543-552; Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: Histology and outcome. Nephrol Dial Transplant. 2005;20(7):1392-1399. doi:10.1093/ndt/gfh830; Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al.; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(7):643.e9-643.e14. doi:10.1016/j.amjmed.2006.08.016; Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: What a hematologist needs to know. Haematologica. 2019;104(3):444-455. doi:10.3324/haematol.2018.205526; Seeliger B, Sznajd J, Robson JC, Judge A, Craven A, Grayson PC, et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (Oxford). 2017;56(7):1154-1161. doi:10.1093/rheumatology/kex075; Watts RA, Suppiah R, Merkel PA, Luqmani R. Systemic vasculitis – Is it time to reclassify? Rheumatology (Oxford). 2011;50(4):643-645. doi:10.1093/rheumatology/keq229; Basu N, Watts R, Bajema I, Baslund B, Bley T, Boers M, et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010;69(10):1744-1750. doi:10.1136/ard.2009.119032; Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):393-399. doi:10.1002/art.41986; Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 2022;74(3):400-406. doi:10.1002/art.41983; Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 2022;74(3):386-392. doi:10.1002/art.41982; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19-28. doi:10.14412/1995-4484-2012-1288
-
5Academic Journal
Συγγραφείς: T. V. Beketova, V. V. Babak, M. D. Suprun, Т. В. Бекетова, В. В. Бабак, М. Д. Супрун
Συνεισφορές: Работа выполнена в рамках научной темы рег. № НИОКТР АААА-А19-119021190148-3
Πηγή: Rheumatology Science and Practice; Vol 59, No 1 (2021); 37-46 ; Научно-практическая ревматология; Vol 59, No 1 (2021); 37-46 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: эозинофильный гранулематоз с полиангиитом, Rituximab, Mepolizumab, В-cells, interleukin-5, ANCA-associated vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, ритуксимаб, меполизумаб, В-клетки, интерлейкин-5, АНЦА-ассоциированный системный васкулит, гранулематоз с полиангиитом, микроскопический полиангиит
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2988/2056; https://rsp.mediar-press.net/rsp/article/view/2988/2057; Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России». 2020 URL: https://rheumatolog.su/news/koronavirusnaya-bolezn-2019-COVID-19-i-immunovospalitelnye-autoimmunnye-revmaticheskie-zabolevaniya/ (accessed: 2020); Бекетова ТВ. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами. Терапевтический архив. 2018;5:13–21 doi:10.26442/terarkh201890513-21; Fornasari PM. COVID-19: Neutrophils “unfriendly fire” imbalance proteolytic cascades triggering clinical worsening and viral sepsis. Potential role explanation for convalescent plasma as “fire hose”. Preprints. 2020;2020050373. doi:10.20944/preprints202005.0373.v1; Luqmani R, Suppiah R, Edwards CJ, Phillip R, Maskell J, Culliford D, et al. Mortality in Wegener’s granulomatosis: A bimodal pattern. Rheumatology (Oxford, England). 2011;50(4): 697–702. doi:10.1093/rheumatology/keq351; Colling ME, Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vascular Medicine. 2020;25(5):471– 478. doi:10.1177/1358863X20932640; Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22(2):95–97.; Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицина ТА и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353–367. doi:10.47360/1995-4484-2020-353-367; Забозлаев ФГ, Кравченко ЭВ, Галлямова АР, Летуновский НН. Патологическая анатомия легких при новой коронавирусной инфекции (COVID-19). Предварительный анализ аутопсийных исследований. Клиническая практика. 2020;11(2):21–37. doi:10.17816/clinpract34849; Kronbichler A, Lee KH, Denicolò S, Choi D, Lee H, Ahn D, et al. Immunopathogenesis of ANCA-associated vasculitis. Int J Mol Sci. 2020;21(19):7319. doi:10.3390/ijms21197319; Talotta R, Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J Clin Cases. 2020;8(17):3621– 3644. doi:10.12998/wjcc.v8.i17.3621; Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi:10.1093/cid/ciaa344; Woodruff MC, Ramonell RP, Cashman KS, Nguyen DC, Saini AS, Haddad N, et al. Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation. medRxiv. 2020.04.29.20083717; doi:10.1101/2020.04.29.20083717; Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20:339–341. doi:10.1038/s41577-020-0321-6; Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–5344. doi:10.1172/JCI138759; Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940–948. doi:10.1080/22221751.2020.1762515; Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi:10.1126/science.abd4585; Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Invest. 2020;130(8): 3950–3953. doi:10.1172/JCI140183; Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;(220):1–13. doi:10.1016/j.trsl.2020.04.007; Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened Innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27:883–890.e2 doi:10.1016/j.chom.2020.04.017; Singh A, Sood N, Narang V, Goyal A. Morphology of COVID-19-affected cells in peripheral blood film. BMJ Case Rep. 2020;13(5):e236117. doi:10.1136/bcr-2020-236117; Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi:10.1038/s41423-020-0402-2; Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020;20:269–270. doi:10.1038/S41577-020-0308-3; Sachdeva M, Gianotti R, Shah M, Bradanini L, Tosi D, Veraldi S, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci. 2020;98:75–81. doi:10.1016/j.jdermsci.2020.04.011; Conde Cardona G, Quintana Pájaro LD, Quintero Marzola ID, Ramos Villegas Y, Moscote Salazar LR. Neurotropism of SARS-CoV-2: Mechanisms and manifestations. J Neurol Sci. 2020;412:116824. doi:10.1016/j.jns.2020.116824; Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol. 2020;19:383–384. doi:10.1016/S1474-4422(20)30109-5; Lazarian G, Quinquenel A, Bellal M, Siavellis J, Jacquy C, Re D, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol. 2020;190:29–31. doi:10.1111/bjh.16794; Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andrès E. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med. 2020;382:e43. doi:10.1056/NEJMc2010472; Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre AS, Thomas M, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. Published Online First. 2020. doi:10.1136/annrheumdis-2020-217573; Craver R, Huber S, Sandomirsky M, McKenna D, Schieffelin J, Finger L. Fatal eosinophilic myocarditis in a healthy 17-year-old male with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2c). Fetal Pediatr Pathol. 2020;39:263–268. doi:10.1080/1551 3815.2020.1761491; Andina D, Noguera-Morel L, Bascuas-Arribas M, Gaitero-Tristán J, Alonso-Cadenas JA, Escalada-Pellitero S, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37:406–411. doi:10.1111/pde.14215; Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, et al. SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: A novel COVID phenotype in children. Pediatrics. 2020;146:e20201711. doi:10.1542/peds.2020-1711; Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet. 2020;395:1771–1778. doi:10.1016/S0140-6736(20)31103-X; Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–414. doi:10.1038/s41584-020-0448-7; Letellier A, Gibelin A, Voiriot G, Fartoukh M, Djibré M. Destructive pulmonary fibrosis after severe COVID-19 pneumonia. Int J Infect Dis. 2020;100:377–378. doi:10.1016/j.ijid.2020.09.026; Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.108393; Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). EClinicalMedicine. 2020;28:100591. doi:10.1016/j.eclinm.2020.100591; Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047. doi:10.26355/eurrev_202004_20875; Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57(Прил. 1): 3–40. doi:10.14412/1995-4484-2019-3-40; Izquierdo JL, Almonacid C, González Y, Del Rio-Bermúdez C, Ancochea J, Cárdenas R, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. Published online ahead of print. 2020 Dec 17;2003142. doi:10.1183/13993003.03142-2020; Matucci A, Caminati M, Vivarelli E, Vianello A, Micheletto C, Menzella F, et al. COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy. 2020. doi:10.1111/all.14516; Banerjee S, George M, Young K, Venkatachalam S, Gordon J, Burroughs C, et al. Effects of the COVID-19 pandemic on patients living with vasculitis. ACR Open Rheumatology. 2020:1–8. doi:10.1002/acr2.11204; Kant S, Morris A, Ravi S, Floyd L, Gapud E, Antichos B, et al. The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. J Nephrol. 2020 Oct 8:1–6. doi:10.1007/s40620-020-00881-3; Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4:e123158. doi:10.1172/jci.insight.123158; Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020:2020.04.09.20059626. doi:10.1101/2020.04.09.20059626; Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480. doi:10.1016/j.clim.2020.108480; Quinti I, Lougaris V, Cinzia Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J All Clin Immunol. 2020;146(1):211–213.e4. doi:10.1016/j.jaci.2020.04.013; Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020;31(5):565–569. doi:10.1111/pai.13263; Fill L, Hadney L, Graven K, Persaud R, Hostoffer R. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020;125(1):112–114. doi:10.1016/j.anai.2020.04.033; Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and Covid-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord. 2020;42:102185. doi:10.1016/j.msard.2020.102185; Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. doi:10.1016/j.msard.2020.102195; Schramm MA, Venhoff N, Wagner D, Thiel J, Huzly D, Craig-Mueller N, et al. COVID-19 in a severely immunosuppressed patient with life-threatening eosinophilic granulomatosis with polyangiitis. Front Immunol. 2020;11:2086. doi:10.3389/fimmu.2020.02086; Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, et al. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis. Published Online First. 2020 Aug 7 doi:10.1136/annrheumdis-2020-218246; Fallet B, Kyburz D, Walker UA. Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B-cells due to treatment with rituximab. Arthritis Rheumatol. 2020;72:1581–1582. doi:10.1002/art.41380; Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Thibault A, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia. Ann Rheum Dis. 2021;80:e10. doi:10.1136/annrheumdis-2020-217549; Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int. 2020;40(12):2015–2021. doi:10.1007/s00296-020-04699-x; Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: A descriptive observational analysis. J Rheumatol. 2020;47:1296. doi:10.3899/jrheum.200507
-
6Academic Journal
Συγγραφείς: T. V. Beketova, I. Yu. Popov, V. V. Babak, Т. В. Бекетова, И. Ю. Попов, В. В. Бабак
Πηγή: Rheumatology Science and Practice; Vol 59, No 6 (2021); 684-692 ; Научно-практическая ревматология; Vol 59, No 6 (2021); 684-692 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: ритуксимаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, rituximab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом, микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3102/2146; Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. doi:10.1002/art.41773; Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: Assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19-27. doi:10.1097/MD.0b013e318205a4c6; Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905; Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi:10.1056/NEJMoa0909169; Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg - Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267-270. doi:10.1016/j.jaci.2009.10.014; Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932. doi:10.1056/NEJMoa1702079; Menditto VG, Rossetti G, Olivari D, Angeletti A, Rocchi M, Gabrielli A, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: A systematic review of observational studies. Rheumatol. 2021;60:1640-1650. doi:10.1093/rheumatology/keab046; Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. Autoimmun Rev. 2021;20:102737. doi:10.1016/j.autrev.2020.102737; Walsh M, Merkel PA, Peh CA, Szpirt WM, Putehal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-631. doi:10.1056/NEJMoa1803537; Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-2188. doi:10.1681/ASN.2007010090; Walsh M, Casian A, Flossmann O, Westman K, Hoglund P, Pusey C, et al.; European Vasculitis Study Group (EUVAS). Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397-402. doi:10.1038/ki.2013.131; Teixeira V, Mohammad AJ, Jones RB, Smith R, Jayne D. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905. doi:10.1136/rmdopen-2019-000905; Crickx E, Machelart I, Lazaro E, Kahn JE, Cohen-Aubart F, Martin T, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vas-culitides: A French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68:702-712. doi:10.1002/art.39472; De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469. doi:10.1002/art.21142; Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771-1780. doi:10.1056/NEJMoa1404231; Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi:10.1056/NEJMoa0802311; Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA. 2010;304:2381-2388. doi:10.1001/jama.2010.1658; Puéchal X, Pagnoux C, Baron G, Quémeneur T, Néel A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg - Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: A randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175-2186. doi:10.1002/art.40205; Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-1091. doi:10.1093/rheumatology/kem029; Kado R, Sanders G, McCune WJ. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy (review). Curr Opin Rheumatol. 2017;29:228-233. doi:10.1097/BOR.0000000000000377; Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207. doi:10.1056/NEJMoa1403290; Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015;122:1262-1268. doi:10.1016/j.ophtha.2015.01.016; Durel CA, Hot A, Trefond L, Aumaitre O, Pugnet G, Samson M, et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 2019;58:1565-1573. doi:10.1093/rheumatology/Kez071; Girard C, Charles P, Terrier B, Bussonne G, Cohen P, Pagnoux C, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener's): A report on 26 cases. Medicine (Baltimore). 2015;94:e1088. doi:10.1097/MD.0000000000001088; Sagmeister MS, Grigorescu M, Schonermarck U. Kidney transplantation in ANCA-associated vasculitis. J Nephrol. 2019;32:919-926. doi:10.1007/s40620-019-00642-x; Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91:1370-1375. doi:10.1097/TP.0b013e31821ab9aa; Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02. doi:10.3205/cto000066; Congdon D, Sherris DA, Specks U, McDonald T. Long-term follow-up of repair of external nasal deformities in patients with Wegener's granulomatosis. Laryngoscope. 2002;112:731-737. doi:10.1097/00005537-200204000-00025; Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - A meta-analysis. Rheumatology (Oxford). 2012;51(1):100-109. doi:10.1093/rheumatology/ker280; Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143-1149. doi:10.1136/annrheumdis-2017-212878
-
7Academic Journal
Συγγραφείς: T. V. Beketova, E. A. Naryshkin, E. V. Arsenyev, M. A. Makarov, Т. В. Бекетова, Е. А. Нарышкин, Е. В. Арсеньев, М. А. Макаров
Πηγή: Rheumatology Science and Practice; Vol 57, No 5 (2019); 597-603 ; Научно-практическая ревматология; Vol 57, No 5 (2019); 597-603 ; 1995-4492 ; 1995-4484
Θεματικοί όροι: эозинофильный гранулематоз с полиангиитом Черджа–Стросс, aseptic necrosis, rituximab, antineutrophil cytoplasmic antibody-associated systemic vasculitis, Wegener’s granulomatosis, microscopic polyangiitis, eosinophilic granulomatosis polyangiitis (or ChurgStrauss syndrome), асептический некроз, ритуксимаб, системные васкулиты, ассоциированные с антинейтрофильными цитоплазматическими антителами, гранулематоз с полиангиитом Вегенера, микроскопический полиангиит
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2784/1888; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133; Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi:10.1002/art.40149; Павлов ВП, Макаров СА, Храмов АЭ. Тотальное эндопротезирование коленного и тазобедренного сустава у пациентов широкого спектра ревматических заболеваний. Медицина (Казахстан). 2014;(10):36-40.; Luqmani R, Bacon P, Moots R, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671-8.; Guillevin L, Pagnoux C, Seror R, et al; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011 Jan;90(1):19-27. doi:10.1097/MD.0b013e318205a4c6; Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012 Dec;14(6):494-500. doi:10.1007/s11926-012-0291-1; Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737-55. doi:10.2106/00004623-196951040-00012; Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi:10.2174/1874312920131210005; Danoff JR, Moss C, Liabaud B, Geller JA. Total knee arthroplasty considerations in Rheumatoid Arthritis. Autoimmun Dis. 2013;2013:Article ID 185340, 6 p. doi:10.1155/2013/185340 36; Храмов АЭ, Макаров МА, Бялик ЕИ и др. Проблемы диагностики, профилактики и лечения перипротезной инфекции у больных ревматическими заболеваниями. Научно-практическая ревматология. 2015;53(5):558-63. doi:10.14412/1995-4484-2015-558-563; McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240-7. doi:10.2215/CJN.05610611; Белов БС, Макаров СА, Бялик ЕИ. Бактериальный (септический) артрит и инфекция протезированного сустава. Научно-практическая ревматология. 2017;55(2):192-200. doi:10.14412/1995-4484-2017-192-200; Lohmann C, Nuechtern J, Junk-Jantsch S, et al. Hypersensitivity reactions in total hip arthroplasty. Orthopedics. 2007;30. doi:10.3928/01477447-20070901-12; Павлов ВП, Вардикова ГН, Макаров СА и др. Эндопротезирование коленного и тазобедренного суставов у больных ревматическими заболеваниями пожилого и старческого возраста. Научно-практическая ревматология. 2003;41(4):101-5. doi:10.14412/1995-4484-2003-1346; Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi:10.1002/art.38231; Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi:10.1136/annrheumdis-2012-202758; Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi:10.1002/acr.22497; Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi:10.3899/jrheum.151373; Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi:10.1016/j.arth.2012.02.022; Бекетова ТВ, Александрова ЕН, Новоселова ТМ и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-58. doi:10.14412/1995-4484-2014-147-158; Рыбников АВ, Бялик EИ, Решетняк ТМ и др. Профилактика венозных тромбоэмболий и риск развития послеоперационных осложнений у пациентов с ревматоидным артритом и остеоартритом при эндопротезировании тазобедренного сустава. Научно-практическая ревматология. 2018;56(6):797-804. doi:10.14412/1995-4484-2018-797-804; Mochizuki T, Ikari K, Yano K, et al. Outcome of direct oral anticoagulant treatment for acute lower limb deep venous thrombosis after total knee arthroplasty or total hip arthroplasty. Mod Rheumatol. 2018;1:1-5. doi:10.1080/14397595.2018.1504396; Januel JM, Romano PS, Couris CM, et al. Clinical and health system determinants of venous thromboembolism event rates after hip arthroplasty: An international comparison. International Methodology Consortium for Coded Health Information (IMECCHI). Med Care. 2018;56(10):862-9. doi:10.1097/MLR.000000000000095; Johanson N, Lachiewicz PF, Licbcrman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroscopy. J Am Acad Orthop Surg. 2009;17(17):183-96. doi:10.2106/JBJS.I.00511; D’Angelo A, Kluft C, Verheijen J, et al. Fibrinolytic shut down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest. 1985;15:308-12 doi:10.1111/j.1365-2362.1985.tb00277; Zoller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis. 2012;2(3):171-83.; Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008 Dec;19(12):2421-9. doi:10.1681/ASN.2008030270; Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi:10.1055/s-0038-1677040; Maino A, Rossio R, Cugno M, et al. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr Vasc Pharmacol. 2012 Sep;10(5):670-5. doi:10.2174/157016112801784594; Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost. 2010 Dec;16(6):628-36. doi:10.1177/1076029609348647; Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 2009 Nov;60(11):3493-500. doi:10.1002/art.24957; Allenbach Y, Seror R, Pagnoux C, et al; French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 Apr;68(4):564-7. doi:10.1136/ard.2008.099051; Hilhorst M, Winckers K, Wilde B, et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013 Dec;40(12):2042-6. doi:10.3899/jrheum.130200; Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi:10.1056/NEJMoa0909905
-
8Academic Journal
Συγγραφείς: T. V. Beketova, Т. В. Бекетова
Πηγή: Rheumatology Science and Practice; Vol 55, No 1 (2017); 12-16 ; Научно-практическая ревматология; Vol 55, No 1 (2017); 12-16 ; 1995-4492 ; 1995-4484 ; 10.14412/rjtao20171
Θεματικοί όροι: ритуксимаб, antineutrophil cytoplasmic antibodies, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, rituximab, антинейтрофильные цитоплазматические антитела, гранулематоз с полиангиитом (Вегенера), микроскопический полиангиит, эозинофильный гранулематоз с полиангиитом
Περιγραφή αρχείου: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2332/1537; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis- 2016-209133. doi:10.1136/annrheumdis-2016-209133; Aasarod K, Bostad L, Hammerstrom J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant. 2001;16:953-60. doi:10.1093/ndt/16.5.953; Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10:2738-43. doi:10.1183/09031936.97.10122738; Corapi KM, Chen JL, Balk EM, et al. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60:62-73. doi:10.1053/j.ajkd.2012.02.330; De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized rial. Ann Intern Med. 2009;150:670-80. doi:10.7326/0003-4819-150-10-200905190-00004; Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187- 98. doi:10.1002/1529-0131(199712)40:123.0.CO;2-H; Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for nduction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-60. doi:10.1136/annrheumdis-2011-200477; Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA- associated renal vasculitis. N Engl J Med. 2010;363:211-20. doi:10.1056/NEJMoa0909169; Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA- associated vasculitis. N Engl J Med. 2010;363:221-32. doi:10.1056/NEJMoa0909905; De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-9. doi:10.1002/art.21142; Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43:1836-40. doi:10.1002/1529- 0131(200008)43: 83.0.CO;2-R; Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl.):S-52-61.; Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis Rheum. 2010;62:9-21. doi:10.1002/art.25061; Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheum. 2015;67:1629-36. doi:10.1002/art.39104; Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am J Kidney Dis. 2003;42:1149-53.doi:10.1053/j.ajkd.2003.08.015; Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535-40. doi:10.1111/j.1523-1755.2004.00917.x; Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford). 2007;46:1087-91. doi:10.1093/rheumatology/kem029; Stegeman CA, Tervaert JWC, de Jong PE, et al. Trimethoprimsulfamethoxazole (Co- trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335:16-20. doi:10.1056/NEJM199607043350103; Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration. Medicine (Baltimore). 2014;93:82-90. doi:10.1097/MD.0000000000000020; Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166-73. doi:10.1002/acr.20176; Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibodyassociated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18. doi:10.1002/art.23800; Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibodyassociated vasculitis. Ann Rheum Dis. 2007;66:605-17. doi:10.1136/ard.2006.062711; Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013;52:875-82. doi:10.1093/rheumatology/kes382; Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)- associated vasculitis: long-term follow-up from a single centre. Scand J Immunol. 2012;76:411-20. doi:10.1111/j.1365-3083.2012.02747.x; Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction- refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010;69:2125-30. doi:10.1136/ard.2010.131953; Fortin PM, Tejani AM, Bassett K, et al. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev. 2013;1:CD007057. doi:10.1002/14651858.CD007057.pub3; Тomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis – a meta-analysis. Rheumatology (Oxford). 2012;51:100-9. doi:10.1093/rheumatology/ker280; Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med. 2007;120:643.e9-14. doi:10.1016/j.amjmed.2006.08.016; Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-32. doi:10.1136/ard.2008.101279; Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371-80. doi:10.1002/art.1780400222; Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27. doi:10.1097/MD.0b013e318205a4c6; De Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol. 2001;55(1):31-8.; Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54:1153-60. doi:10.1093/rheumatology/keu452; Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-96. doi:10.1002/acr.20433
-
9Academic Journal
Συγγραφείς: T. V. Adasheva, O. I. Nesterenko, V. S. Zadionchenko, M. S. Harkova, E. I. Samorukova, Т. В. Адашева, О. И. Нестеренко, В. С. Задионченко, М. С. Харькова, Е. И. Саморукова
Πηγή: The Russian Archives of Internal Medicine; Том 6, № 5 (2016); 63-69 ; Архивъ внутренней медицины; Том 6, № 5 (2016); 63-69 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2016-0-5
Θεματικοί όροι: ANCA-ассоциированные васкулиты, allergic granulomatosis and angiitis, ANCA-associated vasculitis, эозинофильный гранулематоз с полиангиитом
Περιγραφή αρχείου: application/pdf
Relation: https://www.medarhive.ru/jour/article/view/572/538; Захарова Е.В. ANCA-ассоциированные и криоглобулинемические васкулиты: диагностика и лечение (Обзор литературы). Нефрология и диализ. 2005; 1: 6-25. Zakharova E.V. ANCA-associated vasculitis and cryoglobulinemic: diagnosis and treatment (review of literature). Nephrology and Dialysis. 2005; 1: 6-25 [In Russian].; Семенкова Е.Н., Кривошеев О.Г., Стрижаков Л.А. Поражение сердца при системных васкулитах: клиника, диагностика, лечение. Клиническая медицина. 2006; 12: 8-13. Semenkova E.N., Krivosheev O.G. Strizhakov L.A. Heart disease in systemic vasculitis: clinical features, diagnosis, treatment. Clinical medicine. 2006; 12: 8-13 [In Russian].; Федеральные клинические рекомендации по диагностике и лечению системных васкулитов. Ассоциация ревматологов России. http://rheumatolog.ru/experts/klinicheskie-rekomendacii Federal guidelines for the diagnosis and treatment of systemic vasculitis. Association of Rheumatology Russia. http://rheumatolog.ru/experts/klinicheskie-rekomendacii [In Russian].; Федеральные клинические рекомендации. Лабораторная диагностика ревматических заболеваний Ассоциация ревматологов России. http://rheumatolog.ru/experts/klinicheskie-rekomendacii Federal clinical guidelines. Laboratory diagnosis of rheumatic diseases. Association of Rheumatology Russia. http://rheumatolog.ru/experts/klinicheskie-rekomendacii [In Russian].; BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007; 46: 1–11.; Guideline for Management of Vasculitis Syndrome (JCS 2008) — Digest Version — JCS Joint Working Group. Circulation Journal. 2011; 75: 474-503.; Levine A.B., Kalliolias G.,Heaney M. et al. Churg–Strauss Syndrome with Eosinophilic Myocarditis. HSSJ. 2012; 8: 313–319.; Masi A.T., Hunder G.G., Lie J.T., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33: 1094–100.; Meng-Ju Cheng, Pai-Hao Huang, Pin-Wen Liao et al. Multiple Cerebral and Cerebellar Infarcts as the First Clinical Manifestation in a Patient with Churg-Strauss Syndrome: Case Report and Literature Review. Acta Neurol Taiwan. 2012; 21: 169-175.; Noth I., Strek M.E., Leff A.R. Churg-Strauss syndrome. The Lancet. 2003; 361: 587-93.; Pagnoux С. Churg-Strauss Syndrome: Envolving Concepts. Discovery Medicine.2010; 9(46): 243-52.; Sinico P.A., Bottero P. Churg-Strauss angiittis. Best Pract Res Clin Rheumatol. 2003; 23(3): 355-66.; https://www.medarhive.ru/jour/article/view/572
-
10Academic Journal
Συγγραφείς: БЕКЕТОВА ТАТЬЯНА ВАЛЕНТИНОВНА, ВОЛКОВ М.Ю.
Περιγραφή αρχείου: text/html
-
11Academic Journal
Συγγραφείς: Бекетова, Татьяна, Александрова, Е., Новоселова, Т., Сажина, Е., Николаева, Е., Сороцкая, В., Земерова, Е., Нам, И., Никитина, Н., Архангельская, Г., Багаутдинова, З., Дашков, И., Черных, С., Жирова, О., Лушпаева, Ю., Маснева, Л., Афанасьева, И., Арсеньев, А., Кондратенко, И., Башкова, И., Глухова, С., Насонов, Е., Смирнов, А.
Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER''S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM)
Περιγραφή αρχείου: text/html
-
12Academic Journal
Συγγραφείς: Жанузаков М.А., Жакыпова Ж.О., Селедцов В.П., Мукатова А.М., Бопаева М.К., Мусимхан М.К.
Θεματικοί όροι: системные васкулиты, эозинофильный гранулематоз с полиангиитом (синдром Черджа-Стросса), классификация, диагностика
Περιγραφή αρχείου: text/html
-
13Academic Journal
Πηγή: Научно-практическая ревматология.
Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ,ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ,АНТИНЕЙТРОФИЛЬНЫЕ ЦИТОПЛАЗМАТИЧЕСКИЕ АНТИТЕЛА,SYSTEMIC VASCULITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES, 3. Good health
Περιγραφή αρχείου: text/html
-
14Academic Journal
Πηγή: Вестник Алматинского государственного института усовершенствования врачей.
Θεματικοί όροι: системные васкулиты, эозинофильный гранулематоз с полиангиитом (синдром Черджа-Стросса), классификация, диагностика, 3. Good health
Περιγραφή αρχείου: text/html
-
15Academic Journal
Πηγή: Научно-практическая ревматология.
Θεματικοί όροι: СИСТЕМНЫЙ ВАСКУЛИТ, АССОЦИИРОВАННЫЙ С АНТИНЕЙТРОФИЛЬНЫМИ ЦИТОПЛАЗМАТИЧЕСКИМИ АНТИТЕЛАМИ, ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ВЕГЕНЕРА, МИКРОСКОПИЧЕСКИЙ ПОЛИАНГИИТ, ЭОЗИНОФИЛЬНЫЙ ГРАНУЛЕМАТОЗ С ПОЛИАНГИИТОМ ЧЕРДЖА-СТРОС, БИОЛОГИЧЕСКАЯ АНТИ-В-КЛЕТОЧНАЯ ТЕРАПИЯ, РИТУКСИМАБ, WEGENER'S GRANULOMATOSIS WITH POLYANGIITIS, EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS SYNDROM), 3. Good health
Περιγραφή αρχείου: text/html
-
16Academic Journal
Συγγραφείς: Cherkashin D.V., Turdialieva S.A., Mozharovskaya E.A., Kudrina O.M., Taranov A.I.
Πηγή: Marine Medicine; Vol 4, No 2 (2018); 38-47 ; Морская медицина; Vol 4, No 2 (2018); 38-47 ; 2587-7828 ; 2413-5747 ; 10.22328/2413-5747-2018-4-2
Θεματικοί όροι: marine medicine, systemic vasculitis, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome), antineutrophil cytoplasmic antibodies, морская медицина, системные васкулиты, эозинофильный гранулематоз с полиангиитом (синдром Чарджа–Стросса), антинейтрофильные цитоплазматические антитела
Περιγραφή αρχείου: application/pdf
Relation: https://seamed.bmoc-spb.ru/jour/article/view/227/218; https://seamed.bmoc-spb.ru/jour/article/view/227/252
